Oncology Precision Medicine Industry Insights: Market Forecast to 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Oncology Precision Medicine Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The oncology precision medicine market has experienced substantial growth in recent years. Its value is expected to climb from $110.90 billion in 2024 to $125.14 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 12.8%. This historical expansion can be ascribed to the increasing prevalence of cancer, the growing adoption of targeted therapies, rising investments in genomic research, the expanding healthcare infrastructure, and an increased awareness of personalized medicine.

The oncology precision medicine market is projected to experience substantial expansion in the coming years. It is anticipated to reach $201.40 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.6%. This growth throughout the forecast period stems from factors such as a heightened demand for non-invasive cancer diagnostics, a rising inclination towards personalized treatment methods, increased utilization of companion diagnostics, an expanding selection of precision oncology drugs under development, and the growing clinical integration of artificial intelligence tools. Key trends anticipated during this period encompass technological progress in liquid biopsy platforms, breakthroughs in next-generation sequencing, advancements in artificial intelligence for analyzing data, ongoing research and development in identifying biomarkers, and the incorporation of multi-omics into clinical oncology practices.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25853&type=smp

What Are The Key Drivers Of Growth In The Oncology Precision Medicine Market?

An increasing incidence of cancer is anticipated to fuel the expansion of the oncology precision medicine market in the coming years. Cancer involves the unchecked proliferation of aberrant cells, capable of spreading throughout the body and impairing regular physiological processes. This rise in cancer cases stems from aging demographics, where extended longevity contributes to the buildup of deoxyribonucleic acid (DNA) mutations, compromised repair mechanisms, persistent inflammaging, declining immune vigilance, and tissue surroundings that increasingly foster tumor development. Oncology precision medicine offers benefits for cancer patients by delivering individualized therapies, tailored to the distinct genetic profile of each tumor, thereby enhancing efficacy and mitigating adverse reactions. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental body, projected that the approximately 20 million new cases of cancer recorded in 2022 are set to increase by 77% to exceed 35 million cases by 2050. Consequently, the increasing occurrence of cancer is a key impetus for the expansion of the oncology precision medicine market.

What Are The Different Segment Classifications Within The Oncology Precision Medicine Market?

The oncology precision medicine market covered in this report is segmented –

1) By Product Type: Diagnostics, Therapeutics, Inhibitor Drugs, Monoclonal Antibodies, Cell And Gene Therapy, Antiviral And Anti-Retroviral Drugs

2) By Technology: Genomics, Proteomics, Bioinformatics, Other Technologies

3) By Biomarker Types: Genetic Biomarkers, Protein Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers, Other Biomarker Types

4) By Applications: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Kidney Cancer, Liver Cancer, Bladder Cancer, Other Applications

5) By End-Users: Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Diagnostics: Companion Diagnostics, Molecular Diagnostics, Liquid Biopsy, Imaging Diagnostics, Next-Generation Sequencing Assays

2) By Therapeutics: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)

3) By Inhibitor Drugs: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)

4) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors, Radiolabeled Antibodies

5) By Cell And Gene Therapy: CAR-T Cell Therapies, T-Cell Receptor (TCR) Therapies, Tumor-Infiltrating Lymphocyte (TIL) Therapies, Oncolytic Viral Therapies, Gene Editing And Replacement Therapies

6) By Antiviral And Anti-Retroviral Drugs: Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Strand Transfer Inhibitors, Entry Inhibitors, Antiviral Agents Targeting Virus-Related Cancers

Which Market Trends Are Creating New Opportunities In The Oncology Precision Medicine Industry?

Leading companies in the oncology precision medicine market are dedicating efforts to developing inventive solutions, such as molecular tumor board initiatives, to foster multidisciplinary cooperation and refine personalized treatment planning. Molecular tumor boards are multidisciplinary groups of specialists who assess and interpret complex genetic and molecular test results to propose individualized cancer treatment strategies. For example, in April 2025, McKesson Corporation, a US-based healthcare services and information technology firm, unveiled its Precision Care Companion initiative designed to bolster biomarker-driven cancer care by supplying education, technological improvements, and operational aid to oncology practices. This comprehensive undertaking gathers physicians, clinical staff, business leaders, and pharmaceutical partners to establish a collaborative setting that accelerates the integration of advanced genomic testing and targeted therapies, ultimately enabling providers to deliver more personalized and impactful cancer treatments while enhancing patient outcomes.

Who Are The Key Multinational Companies Dominating The Oncology Precision Medicine Market?

Major companies operating in the oncology precision medicine market are Roche Holding AG, Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, Gilead Sciences Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Agilent Technologies Inc., Illumina Inc., bioMérieux S.A., Bio-Rad Laboratories Inc., Exact Sciences Corporation, Almac Group Limited, OPKO Health Inc., Natera Inc., Myriad Genetics Inc., Pacific Biosciences of California Inc., Asuragen Inc., BGI Group, ANGLE plc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/oncology-precision-medicine-global-market-report

How Is Oncology Precision Medicine Market Demand Varying Across Different Regions?

North America was the largest region in the oncology precision medicine market in 2024. The regions covered in the oncology precision medicine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Oncology Precision Medicine Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25853&type=smp

Browse Through More Reports Similar to the Global Oncology Precision Medicine Market 2025, By The Business Research Company

Precision Medicine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/precision-medicine-global-market-report

Oncology Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Oncology Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795